Retrospective Analysis of Hungarian HTA Submissions Under the Former National Health Economics Guideline
Author(s)
András M. Hetényi, MSc, Nikolett Jónás, MSc, Hanna Bordás-Lóczi, MSc, Dorottya Rudnai-Rákoczi, MSc, Mónika Nagyi-Német, MSc, Gyöngyi Márton-Farkas, MSc, Adrienn Barna, MSc, Jácinta Juhász, MD.
National Center for Public Health and Pharmacy, Budapest, Hungary.
National Center for Public Health and Pharmacy, Budapest, Hungary.
OBJECTIVES: The NCPHP Department of Technology Assessment is the national HTA body of Hungary, as such we participated in last year’s renewal of the Hungarian HTA guideline. Part of this renewal process was a retrospective analysis of the effect of the last guideline, which came to effect in 2021. It’s main addition to the HTA process was the introduction of differentiated cost-effectiveness thresholds based on added clinical value. We had analyzed the distribution of the innovative drugs between Nov 2021 - Oct 2024 and estimated the effect the renewed guideline would have had on these.
METHODS: Out of 452 submissions we filtered out the 174 relevant to our research subject, based on orphan status and analysis type. We created descriptive statistics for the incremental QALY, the added health benefit indicator (TEM in Hungarian), the cost-effectiveness conclusion allowing us to get an overview of the last three years of HTA dossiers.
RESULTS: We found that the majority of innovative drugs were categorized as low added health benefit based on the applicant calculated QALY gains and had fallen under the lowest cost-effectiveness threshold. Although the local lowest ICER threshold was higher than the regional average, around one third of submissions were not cost-effective at the requested price level.
CONCLUSIONS: Based on our findings we expect minor change regarding cost-effectiveness following the recent introduction of the updated guideline.
METHODS: Out of 452 submissions we filtered out the 174 relevant to our research subject, based on orphan status and analysis type. We created descriptive statistics for the incremental QALY, the added health benefit indicator (TEM in Hungarian), the cost-effectiveness conclusion allowing us to get an overview of the last three years of HTA dossiers.
RESULTS: We found that the majority of innovative drugs were categorized as low added health benefit based on the applicant calculated QALY gains and had fallen under the lowest cost-effectiveness threshold. Although the local lowest ICER threshold was higher than the regional average, around one third of submissions were not cost-effective at the requested price level.
CONCLUSIONS: Based on our findings we expect minor change regarding cost-effectiveness following the recent introduction of the updated guideline.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HTA288
Topic
Economic Evaluation, Health Technology Assessment, Organizational Practices
Topic Subcategory
Systems & Structure, Value Frameworks & Dossier Format
Disease
No Additional Disease & Conditions/Specialized Treatment Areas